Cannformatics waxay ku dhawaaqday inay aqoonsatay 22 cusub oo suurtagal ah oo ku saleysan xashiishadda Cannabis-Responsive ™ biomarkers oo ku jira candhuufta carruurta qaba cudurka autism-ka (ASD). Dhammaan 22 biomarkers waxay u dhaqaaqeen noocyada kala duwan ee jireed ee carruurta sida caadiga ah soo koraya ka dib daaweynta cannabis ee lagu guuleystay. Tilmaamayaashan biomarkers waxaa ka mid ah dufannada habdhiska dhexe ee neerfayaasha kuwaas oo ugu horrayn la xiriira dhaqdhaqaaqa gacanta ee maskaxda taas oo muujinaysa awoodda xashiishadda caafimaad ee saameyn ku yeelanaysa shaqada neerfaha ee carruurta qaba ASD. Daah-furayaashani waxay sii wadaan horumarka ay shirkaddu ku samaynayso adeegga daawaynta ee gaarka loo leeyahay oo ah kheyraad bixiyeyaasha daryeelka caafimaadka iyo bukaannada doonaya inay isticmaalaan dawooyinka iyo alaabooyinka ku salaysan cannabinoid si loogu daweeyo xaalado caafimaad oo adag.
Shirkaddu waxay natiijadeeda ku daabacday joornaalka Cannabis iyo Cannabinoid Research warqad cinwaan looga dhigay, "Awoodda cannabis-ku-salaysan biomarkers-ka-celinta candhuufta si loo qiimeeyo daaweynta xashiishadda cannabis ee carruurta leh ASD." Warqadani waa warqadii labaad ee ka soo baxda daraasadda ASD Pilot ee shirkadda. Waraaqdii ugu horreysay oo la daabacay Disembar 2021 waxay aasaastay biomarkers-ka jawaab celinta Cannabis-ka oo ah aalad caalami ah oo lagu cabbiro saameynta xashiishadda caafimaadka. Si wada jir ah labada warqadood waxay muujinayaan suurtagalnimada candhuuf-ku-saleysan-xashiish-ku-soo-celinta biomarkers si ay u noqdaan aalad labada bukaan-socod ee daaweysa bukaannada qaba xashiishadda caafimaadka iyo shirkadaha sayniska nolosha ee soo saaraya dawooyinka iyo codsiyada ku saleysan cannabinoid-ka soo socda.
"Markaan furayno habka ficilka xashiishadda cannabis, waxaan muujineynaa in biomarkers-ka jawaab celinta Cannabis ay siin karaan shirkadaha sayniska nolosha iyo dhakhaatiirta qalab cusub oo lagu fahmo doorka xashiishadda si loo ilaaliyo homeostasis ee habka dhexe ee neerfayaasha ee carruurta qaba ASD. Daraasadani waxay sidoo kale furaysaa fursado cusub oo lagu qiimeeyo daaweynta xashiishadda caafimaadka ee cudurada neerfayaasha sida cudurka Alzheimers, cudurka Parkinson iyo ALS, kuwaas oo qaar ka mid ah kuwan ka mid ah kuwan suurtagalka ah ee Cannabis-Responsive biomarkers ayaa loo yaqaan inay door ka ciyaaraan ", ayuu yiri Itzhak Kurek, PhD. , Maamulaha guud iyo aasaasaha Cannformatics. "Waxaan hadda ku jirnaa kor u qaadista caasimadda loo baahan yahay si aan u bilowno madal adeegga ASD oo aan ku fidinno cudurrada neurodegenerative."
"Daabacaadda warqaddan labaad waxay u tahay waqti muhiim u ah Cannformatics maadaama ay si buuxda u ansaxisay tignoolajiyadayada waxayna si cad noogu meelaynaysaa hogaamiyaha cilmiga bayoolajiga ee daaweynta xashiishadda caafimaadka," ayuu yidhi Madaxa Ganacsiga ee Kenneth Epstein iyo aasaasaha Cannformatics. "Waxaan sii wadnaa inaan u mahadcelino carruurta iyo qoysaska ka qaybqaatay daraasadda iyo sidoo kale kafaala-qaadayaashayada Canniatric iyo Gelitaanka Dhirta oo dhan ee Ootiisamka. Natiijooyinka ka soo baxay daraasaddan ayaa si wanaagsan uga gudubnay wixii aan filaynay.”
